Cyclacel Pharmaceuticals Inc (NAS:CYCC)
$ 2.34 -0.1 (-4.1%) Market Cap: 3.42 Mil Enterprise Value: 229,000.00 PE Ratio: 0 PB Ratio: 4.09 GF Score: 28/100

Q4 2018 Cyclacel Pharmaceuticals Inc Earnings Call Transcript

Mar 27, 2019 / 08:30PM GMT
Release Date Price: $270 (-2.20%)
Operator

Good afternoon, and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2018 Results Conference Call and Webcast. (Operator Instructions) The company will also be accepting a limited number of questions submitted via e-mail to the address, [email protected]. (Operator Instructions) Please note that today's call is being recorded.

I would now like to turn the conference call over to Alex. Please go ahead.

Alexander Fudukidis
Russo Partners, LLC - VP

Good afternoon, everyone, and thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the fourth quarter and full year ending December 31, 2018.

Before turning the call over to management, I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 as amended.

As set forth in our press release, forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot